Who are Citius Oncology, Inc.'s main suppliers?

Citius Oncology, Inc. (CTOR) key suppliers include: CITIUS-PHARMA, INTEGRIS-PHARMA-S-A, Citius Pharmaceuticals, Inc., McKesson Corporation, McKesson Corporation. View the full supplier network at chainsifter.com/chain/CTOR.

Who are Citius Oncology, Inc.'s major customers?

Citius Oncology, Inc. (CTOR) key customers include: Citius Pharmaceuticals, Inc., CITIUS-PHARMA, McKesson Corporation, McKesson Corporation, EISAI-CO-LTD and 3 more. View the full customer network at chainsifter.com/chain/CTOR.

What sector is Citius Oncology, Inc. in?

Citius Oncology, Inc. (CTOR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Citius Oncology, Inc. Supplier List (CTOR): 5 Verified Suppliers

5Suppliers

8Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Citius Oncology, Inc. (CTOR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

3Distinct source URLs

6High confidence

0.768Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Citius Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CITIUS-PHARMA	CITIUS-PHARMA	92%	The Company and Citius Pharma entered into the A&R Shared Services Agreement and under the terms of the agreement, Citius Pharma provides management and scientific services to us
INTEGRIS-PHARMA-S-A	INTEGRIS-PHARMA-S-A	90%	On October 7, 2025, we entered into an exclusive distribution agreement with Integris Pharma S.A.
CTXR	Citius Pharmaceuticals, Inc.	72%	Reciprocal relationship from CTXR graph: s, NoveCite had to maintain Novellus’s ownership at % by issuing additional shares to Novellus. In July 2021, Novellus was acquired by Brooklyn ImmunoTherapeu…
MCK	McKesson Corporation	72%	Reciprocal relationship from MCK graph: Reciprocal relationship from CTOR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CTOR graph: adds the risk of import restrictions,…
MCK	McKesson Corporation	72%	adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…

Citius Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
CTXR	Citius Pharmaceuticals, Inc.	92%	Reciprocal relationship from CTXR graph: Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR g…
CITIUS-PHARMA	CITIUS-PHARMA	90%	Since its inception, Citius Pharmaceuticals, Inc. ("Citius Pharma") has funded and continues to fund the Company.
MCK	McKesson Corporation	72%	Reciprocal relationship from MCK graph: Reciprocal relationship from CTOR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect…
MCK	McKesson Corporation	72%	adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
EISAI-CO-LTD	EISAI-CO-LTD	62%	Company has deposited the estimated co-pay assistance reflected and included in the gross-to-net adjustments. Three Months Ended Six Months Ended March 31, 2026 March 31, 2026 Gross Product Revenue $…
INNOVATION-PARTNERS	INNOVATION-PARTNERS	62%	adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
K-CITIUS-ONCOLOGY-INC	K-CITIUS-ONCOLOGY-INC	62%	her any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recove…
LABORATORIES-LTD	LABORATORIES-LTD	62%	Company has deposited the estimated co-pay assistance reflected and included in the gross-to-net adjustments. Three Months Ended Six Months Ended March 31, 2026 March 31, 2026 Gross Product Revenue $…

Citius Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CTOR-DEBT	Debt stack $3.8M	90%	Market cache reports total debt of $3.8M.
CTOR-DEBT-8914	Warrants outstanding: 816738	90%	xbrl warrant detail from xbrl 2025-12-10.

Citius Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Citius Oncology, Inc..

Citius Oncology, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Citius Oncology, Inc..

Citius Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MCK	McKesson Corporation	100.00	1	['customer', 'supplier']
CTXR	Citius Pharmaceuticals, Inc.	59.25	1	['customer', 'supplier']
COR	Cencora, Inc.	50.00	2
CHRS	Coherus Oncology, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
AMPH	Amphastar Pharmaceuticals, Inc.	50.00	2
SUPN	Supernus Pharmaceuticals, Inc.	50.00	2
ADCT	ADC Therapeutics SA	50.00	2
CAH	Cardinal Health, Inc.	50.00	2
CLH	Clean Harbors, Inc.	50.00	2
HCA	HCA Healthcare, Inc.	50.00	2
APO-PA	Apollo Global Management, Inc.	50.00	2
ARDX	Ardelyx, Inc.	50.00	2
HLNCF	Haleon plc	50.00	2
CRM	Salesforce, Inc.	50.00	2
GILD	Gilead Sciences, Inc.	50.00	2
HALO	Halozyme Therapeutics, Inc.	50.00	2
GRDN	Guardian Pharmacy Services, Inc.	50.00	2
HLN	Haleon plc	50.00	2
JAZZ	Jazz Pharmaceuticals plc	50.00	2

Citius Oncology, Inc. Supply Chain